
|Articles|December 12, 2012
Zytiga now available for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Janssen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Gaps Between Expectations and Effects on Long COVID Contribute to Trust in Vaccines
2
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
3
American Pharmacists Month: How Community Pharmacy Innovation Relies on Expansion, Collaboration
4
Pharmacies Should Be Proactive in Expanding Clinical Services, Reimbursement Pathways | NCPA 2025
5


























































































































































